The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
about
The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The selective MEK1 inhibitor S ...... arcinoma in vitro and in vivo.
@ast
The selective MEK1 inhibitor S ...... arcinoma in vitro and in vivo.
@en
type
label
The selective MEK1 inhibitor S ...... arcinoma in vitro and in vivo.
@ast
The selective MEK1 inhibitor S ...... arcinoma in vitro and in vivo.
@en
prefLabel
The selective MEK1 inhibitor S ...... arcinoma in vitro and in vivo.
@ast
The selective MEK1 inhibitor S ...... arcinoma in vitro and in vivo.
@en
P2093
P2860
P356
P1433
P1476
The selective MEK1 inhibitor S ...... arcinoma in vitro and in vivo.
@en
P2093
Jianfeng Wang
Jiwei Huang
Xuejiao Leng
Yiran Huang
P2860
P304
20825-20833
P356
10.18632/ONCOTARGET.15346
P407
P577
2017-02-14T00:00:00Z